 Protease Inhibitors
"Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
| Descriptor ID |
D011480
|
| MeSH Number(s) |
D27.505.519.389.745
|
| Concept/Terms |
Protease Inhibitors- Protease Inhibitors
- Inhibitors, Protease
- Endopeptidase Inhibitors
- Inhibitors, Endopeptidase
- Protease Inhibitor
- Inhibitor, Protease
- Peptide Hydrolase Inhibitors
- Hydrolase Inhibitors, Peptide
- Inhibitors, Peptide Hydrolase
- Peptide Peptidohydrolase Inhibitors
- Inhibitors, Peptide Peptidohydrolase
- Peptidohydrolase Inhibitors, Peptide
- Protease Antagonists
- Antagonists, Protease
- Antiproteases
- Peptidase Inhibitors
- Inhibitors, Peptidase
|
Below are MeSH descriptors whose meaning is more general than "Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protease Inhibitors".
This graph shows the total number of publications written about "Protease Inhibitors" by people in this website by year, and whether "Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 3 | 3 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 2 | 2 | | 2002 | 1 | 2 | 3 | | 2004 | 2 | 3 | 5 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 0 | 2 | | 2007 | 2 | 1 | 3 | | 2008 | 3 | 2 | 5 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 3 | 5 | | 2011 | 5 | 0 | 5 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 1 | 1 | | 2014 | 2 | 3 | 5 | | 2015 | 0 | 1 | 1 | | 2017 | 4 | 0 | 4 | | 2018 | 3 | 0 | 3 | | 2019 | 0 | 2 | 2 | | 2020 | 3 | 1 | 4 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Protease Inhibitors" by people in Profiles.
-
Kramer L, Sarkar A, Foderaro T, Markley AL, Lee J, Edstrom H, Sharma S, Gill E, Traylor MJ, Fox JM. Genetically Encoded Detection of Biosynthetic Protease Inhibitors. ACS Synth Biol. 2023 01 20; 12(1):83-94.
-
Brooks KM, Pinilla M, Stek AM, Shapiro DE, Barr E, Febo IL, Paul ME, Deville JG, George K, Knowles K, Rungruengthanakit K, Browning R, Chakhtoura N, Capparelli EV, Mirochnick M, Best BM. Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. J Acquir Immune Defic Syndr. 2022 07 01; 90(3):343-350.
-
Hicks EG, Kandel SE, Lampe JN. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors. Bioorg Med Chem Lett. 2022 06 15; 66:128732.
-
Goel K, Serban KA. The multifaceted protease-anti-protease imbalance in COVID-19. EBioMedicine. 2022 04; 78:103973.
-
Freitas BT, Ahiadorme DA, Bagul RS, Durie IA, Ghosh S, Hill J, Kramer NE, Murray J, O'Boyle BM, Onobun E, Pirrone MG, Shepard JD, Enos S, Subedi YP, Upadhyaya K, Tripp RA, Cummings BS, Crich D, Pegan SD. Exploring Noncovalent Protease Inhibitors for the Treatment of Severe Acute Respiratory Syndrome and Severe Acute Respiratory Syndrome-Like Coronaviruses. ACS Infect Dis. 2022 03 11; 8(3):596-611.
-
Ebenezer O, Bodede O, Awolade P, Jordaan MA, Ogunsakin RE, Shapi M. Medicinal plants with anti-SARS-CoV activity repurposing for treatment of COVID-19 infection: A systematic review and meta-analysis. Acta Pharm. 2022 Jun 01; 72(2):199-224.
-
Greene SJ, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Luo N, Samsky MD, Heidenreich PA, Laskey WK, Yancy CW, Peterson PN, Curtis LH, Hernandez AF, Fonarow GC, O'Brien EC. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc. 2021 08 17; 10(16):e021459.
-
Dickert NW, Mitchell AR, Venechuk GE, Matlock DD, Moore MA, Morris AA, Pierce KJ, Speight CD, Allen LA. Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost. Circ Cardiovasc Qual Outcomes. 2020 12; 13(12):e007070.
-
Wang Z, Rahkola J, Redzic JS, Chi YC, Tran N, Holyoak T, Zheng H, Janoff E, Eisenmesser E. Mechanism and inhibition of Streptococcus pneumoniae IgA1 protease. Nat Commun. 2020 11 27; 11(1):6063.
-
Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020 11 01; 75(11):3303-3310.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|